Antidepressant Drugs Market Size By Drug Class (Selective Serotonin Reuptake Inhibitors {SSRIs}, Serotonin-norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants), By Application (Major Depressive Disorder, Obsessive-compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Published Date: Sep 2021  |  Report ID: GMI2505  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 120   |   Base Year: 2020




Summary Table of Contents Industry Coverage Methodology

Industry trends

Antidepressant Drugs Market size exceeded USD 13.5 billion in 2020 and is anticipated to grow at over 7.2% CAGR between 2021 and 2027. Broader accessibility with number of available products in the market will significantly boost the product sales, thus benefiting the overall industry growth.
 

Antidepressant Drugs Market Overview

Get more details on this report - Request Free Sample PDF
 

Supportive government initiatives to broaden accessibility of basic treatment for all mental health conditions will favour the market expansion. For instance, the European Commission launched RECOVER-E project under Horizon-2020 in 2018 for implementation of mental health service delivery model to improve mental health of population in Europe. Additionally, the Government of India proposed budget of more than USD 80 million for mental healthcare in its union budget for 2021-2022.
 

Need to expand treatment accessibility with growing disease prone population will stimulate the antidepressant drugs market value

Increasing burden of depression and associated mental health conditions will flourish the demand for antidepressant drugs. As per the World Health Organization, nearly 40 million people are suffering through depressive disorders in Europe that accounts for approximately 4.3% of overall regional population. Moreover, according to the Centers for Disease Control and Prevention, about 16 million adult individuals’ experiences depression in America every year. Such large patient pool will escalate the demand for antidepressant drugs. In addition, as per the World Health Organization, 3 out of 4 people suffering from depression does not receive proper treatment. This represents industry potential to business leaders for the market progression.
 

Antidepressant drugs market continued to witness revenue growth during COVID-19 pandemic. Emergence of COVID-19 has triggered one of the worst jobs crisis in several sectors that has led to economic instability. Along with economic instability, social isolation with movement restrictions has resulted in depression and anxiety among population.
 

Expanding availability of effective therapies will propel the demand for serotonin-norepinephrine reuptake inhibitors

Serotonin-norepinephrine reuptake inhibitors (SNRIs) segment held around 9% of the antidepressant drugs market share in 2020. SNRIs are used as second line drug regime to treat patients suffering from anxiety and depression disorders. Its expanding applications in the treatment of abnormal psychological changes with better efficacy will enhance the product demand. Furthermore, these drugs are also proven to be effective for treatment of long-term nerve pain in anxiety disorders.
 

High product demand with rising incidence of generalized anxiety disorder will offer lucrative growth opportunities

Antidepressant Drugs Market Size

Get more details on this report - Request Free Sample PDF
 

Generalized anxiety disorder (GAD) segment in the antidepressant drugs market is expected to showcase 7.8% growth rate through 2027. According to the Anxiety and Depression Association of America (ADAA), among 6.8 million people suffering from GAD, only 43.2% patients are receiving treatment in the U.S. Significant portion of population inclining towards overthinking about everyday life events contributes to rising patient pool.
 

Infrastructure development to address the increasing need of mental health care will continue to impel the product demand in European region

Europe antidepressant drugs market accounted for more than 25% of revenue share in 2020 led by the growing awareness about therapies for mental disorders. Along with disease prevalence, rising disposable income, high healthcare spending, infrastructure development and availability of skilled workforce to address patient pool will foster the number of patients accessing treatment. Moreover, product launches to address concerns regarding various anxiety disorders by regional market participants expands drugs availability. Further, strong pipeline resulting into new product launches in future will spur revenue growth in the region.
 

New product innovations and partnerships will offer competitive advantage to the market players

The global antidepressant drugs market consists of numerous companies including Eli Lilly & Company, N.V. Organon, Takeda Pharmaceuticals, Janssen Pharmaceuticals, Novartis AG, Opko Health, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Patheon Inc, Sandoz Inc., Intra-Cellular Therapies, Otsuka Pharmaceutical, Zhejiang NHU Company Ltd. and Sun Pharmaceuticals Pvt. Ltd. These leaders have undertaken several growth strategies such as partnerships, business expansion, acquisitions and product launches to increase their market position.
 

Some of the recent industry developments:

  • In June 2020, Sage Therapeutics announced collaboration with Biogen Inc. to develop and commercialize zuranolone for treatment of postpartum depression (PPD) and major depressive disorder (MDD). Such developments allow companies to sustain their market position.
     
  • In August 2019, Lupin Limited launched generic fluoxetine tablet for treatment of depression disorders such as major depressive disorder, panic disorder, obsessive compulsive disorder and several others. This has strengthened product portfolio of the company in the market.
     
  • In May 2018, Allergen plc. announced the acquisition of AGN-241751 antidepressant N-methyl-D-aspartate receptor modulator drug from Aptinyx Inc. This has enhanced development capabilities of the firm.
     

The antidepressant drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027 for the following segments:

Market, By Drug class

  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
  • Tricyclic Antidepressants
  • Others

Market, By Application

  • Major Depressive Disorder
  • Obsessive-compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Turkey
    • Sweden
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia

 

Frequently Asked Questions (FAQ) :

Global market size of antidepressant drugs was over USD 13.5 billion during 2020 and is expected to witness around 7.2% CAGR up to 2027 with increased access to a large number of products.
Serotonin-norepinephrine reuptake inhibitors (SNRIs) class of drugs held nearly 9% of global antidepressant drugs industry share in 2020 and will grow due to increasing cases of depression and anxiety disorders.
The key types of antidepressant drugs include Serotonin-norepinephrine Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors {SSRIs} and Tricyclic Antidepressants.
Europe market held more than 25% of revenue share in 2020 and will expand with rising awareness and acceptance of mental disorders and related therapies.
Leading antidepressant drug manufacturers worldwide include Novartis, GlaxoSmithKline, Pfizer, Eli Lilly & Company, Janssen Pharmaceuticals, Bristol-Myers Squibb, Sandoz Inc., Otsuka Pharmaceutical and Sun Pharmaceuticals, among some others.

Premium Report Details

  • Published Date: Sep 2021
  • Pages: 120
  • Tables: 137
  • Charts / Figures: 11
  • Companies covered: 15
  • Countries covered: 20

Get a report that explains COVID-19 impact on this market

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X